<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234285</url>
  </required_header>
  <id_info>
    <org_study_id>10-0595</org_study_id>
    <nct_id>NCT01234285</nct_id>
  </id_info>
  <brief_title>Safety of Heparin in Patients With Septic Shock</brief_title>
  <official_title>Safety of Heparin Anticoagulation for Prevention of Death in Patients With Septic Shock.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a syndrome comprised of a systemic inflammatory response, signs of tissue
      hypoperfusion, and organ in the setting of presumed infection. Heparin, in addition to being
      an anticoagulant, is also a well-known antiinflammatory. The investigators believe that
      unfractionated heparin has the potential to save the lives of septic patients at a
      drastically reduced cost. This is a dose escalation study to determine the safety of
      increasing levels of heparin in this patient population; compare markers of anticoagulation
      and inflammation between treatment groups; and compare clinical outcomes between groups.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sara Cheng, MD has left the Univ. of Colorado and the study has been closed.
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of major bleeding</measure>
    <time_frame>This outcome will be measured for an average of 30 days</time_frame>
    <description>Defined as:decrease in hemoglobin greater than 2g/dl and/or transfusion of 2 or more units of packed red blood cells.
However, if there are obvious other reasons for bleeding, such as within 12 hours of major surgery, coagulopathy unrelated to heparin or an anatomical basis.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>intravenous heparin aPTT 40-50 seconds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 11-15: IV heparin, target aPTT range 40-50 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intravenous heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 26-40: IV heparin, target range aPTT 50-60 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 41-55 IV heparin, target aPTT range 60-70 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sq heparin three times a day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients 1-10 will receive subcutaneous heparin three times a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin</intervention_name>
    <description>intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.</description>
    <arm_group_label>intravenous heparin aPTT 40-50 seconds</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin</intervention_name>
    <description>intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.</description>
    <arm_group_label>intravenous heparin</arm_group_label>
    <arm_group_label>Intravenous heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin</intervention_name>
    <description>intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.</description>
    <arm_group_label>intravenous heparin</arm_group_label>
    <arm_group_label>Intravenous heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin</intervention_name>
    <description>5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.</description>
    <arm_group_label>sq heparin three times a day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-90 in the medical or surgical intensive care unit

          2. Within 24 hours of diagnosis with sepsis as defined by the Bone criteria (see Appendix
             A);

          3. Acute Physiology and Chronic Health Evaluation (APACHE II) score of &gt; 25;

          4. Signed consent

        Exclusion Criteria:

          1. Currently therapeutically anticoagulated for known thrombotic diagnosis (myocardial
             infarction, venous thromboembolism) known molecular hypercoagulable state (Factor V
             Leiden, lupus anticoagulant, antiphospholipid antibody syndrome); or use of
             cardiopulmonary support machines (left-ventricular assist device, intra-aortic balloon
             pump, veno-venous ultrafiltration, or extracorporeal membrane oxygenation.

          2. History of gastrointestinal or cerebral hemorrhage within past 3 months;

          3. Active bleeding;

          4. Known allergy or sensitivity to heparin;

          5. History of heparin-induced thrombocytopenia

          6. Organ transplantation recipient -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Cheng, MD;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marshall JC. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med. 2001 Jul;29(7 Suppl):S99-106. Review.</citation>
    <PMID>11445742</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Gupta D. Anticoagulation in sepsis: is low-dose heparin as effective as activated protein C? Intensive Care Med. 2005 Sep;31(9):1297-8. Epub 2005 Jul 9.</citation>
    <PMID>16007415</PMID>
  </reference>
  <reference>
    <citation>Zarychanski R, Doucette S, Fergusson D, Roberts D, Houston DS, Sharma S, Gulati H, Kumar A. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008 Nov;36(11):2973-9. doi: 10.1097/CCM.0b013e31818b8c6b.</citation>
    <PMID>18824906</PMID>
  </reference>
  <reference>
    <citation>Robertson MS. Heparin: the cheap alternative for immunomodulation in sepsis? Crit Care Resusc. 2006 Sep;8(3):235-8. Review.</citation>
    <PMID>16930112</PMID>
  </reference>
  <reference>
    <citation>Derhaschnig U, Pernerstorfer T, Knechtelsdorfer M, Hollenstein U, Panzer S, Jilma B. Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med. 2003 Apr;31(4):1108-12.</citation>
    <PMID>12682480</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>May 19, 2014</last_update_submitted>
  <last_update_submitted_qc>May 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

